Cytokine-induced interleukin-1 receptor antagonist protein expression in genetically engineered equine mesenchymal stem cells for osteoarthritis treatment

Simone Gabner1 | Reinhard Ertl2 | Karsten Velde3 | Matthias Renner4 | Florien Jenner3 | Monika Egerbacher1 | Juraj Hlavaty1

1 Institute of Pathology and Forensic Veterinary Medicine, Working Group Histology and Embryology, University of Veterinary Medicine Vienna, Vienna, Austria
2 VetCORE, Facility for Research, University of Veterinary Medicine, Vienna, Austria
3 Equine University Hospital, University of Veterinary Medicine Vienna, Vienna, Austria
4 Division of Medical Biotechnology, Paul Ehrlich-Institut, Langen, Germany

Correspondence
Juraj Hlavaty, Institute of Anatomy, Histology and Embryology, University of Veterinary Medicine, Veterinaerplatz 1, A-1210 Vienna, Austria.
Email: juraj.hlavaty@vetmeduni.ac.at

Funding information
Bright Sparks Funding, Vetmeduni Vienna, Austria, Grant/Award Number: PP10014701

Abstract

Background: A combination of tissue engineering methods employing mesenchymal stem cells (MSCs) together with gene transfer takes advantage of innovative strategies and highlights a new approach for targeting osteoarthritis (OA) and other cartilage defects. Furthermore, the development of systems allowing tunable transgene expression as regulated by natural disease-induced substances is highly desirable.

Methods: Bone marrow-derived equine MSCs were transduced with a lentiviral vector expressing interleukin-1 receptor antagonist (IL-1Ra) gene under the control of an inducible nuclear factor-kappa B-responsive promoter and IL-1Ra production upon pro-inflammatory cytokine stimulation [tumor necrosis factor (TNF)α, interleukin (IL)-1β] was analysed. To assess the biological activity of the IL-1Ra protein that was produced and the therapeutic effect of IL-1Ra-expressing MSCs (MSC/IL-1Ra), cytokine-based two- and three-dimensional in vitro models of osteoarthritis using equine chondrocytes were established and quantitative real-time polymerase chain reaction (PCR) analysis was used to measure the gene expression of aggrecan, collagen IIA1, interleukin-6, interleukin-8, matrix metalloproteinase-1 and matrix metalloproteinase-13.

Results: A dose-dependent increase in IL-1Ra expression was found in MSC/IL-1Ra cells upon TNFα administration, whereas stimulation using IL-1β did not lead to IL-1Ra production above the basal level observed in nonstimulated cells as a result of the existing feedback loop. Repeated cycles of induction allowed on/off modulation of transgene expression. In vitro analyses revealed that IL-1Ra protein present in the conditioned medium from MSC/IL-1Ra cells blocks OA onset in cytokine-treated equine chondrocytes and co-cultivation of MSC/IL-1Ra cells with osteoarthritic spheroids alleviates the severity of the osteoarthritic changes.

Conclusions: Thus, pro-inflammatory cytokine induced IL-1Ra protein expression from genetically modified MSCs might represent a promising strategy for osteoarthritis treatment.

KEYWORDS
bone marrow-derived MSCs, cartilage defect, cell-based therapy, inducible promoter

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2018 The Authors. The Journal of Gene Medicine published by John Wiley & Sons, Ltd
Osteoarthritis (OA) is a multifactorial condition of diverse aetiology that affects all tissues in synovial joints and culminates in structural and functional joint ‘organ’ failure, including loss and erosion of articular cartilage, subchondral bone remodelling, synovial inflammation and osteophyte formation. OA is the most common chronic articular disorder and affects most mammalian species, including humans, horses, dogs, cats and sheep, all of which exhibit a similar pathogenesis. The pathophysiological events start with the degradation of extracellular matrix components of the articular cartilage either as a result of accumulated repetitive micro-damage, a major traumatic event, or metabolic and biochemical factors, and are driven principally by an early innate immune response that progressively catalyses degenerative changes. The disease process is difficult to interrupt and results in a vicious circle of inflammation and degradation, leading to a gradual loss of joint function and pain.

A number of putative mediators, including proinflammatory cytokines, growth factors and radicals, are implicated in the process, although pro-inflammatory cytokines appear to play a dominant role in the initiation and progression of articular cartilage destruction by disturbing the dynamic articular equilibrium between anabolic and catabolic processes. Interleukin (IL)-1β is one of the key arthritogenic triggers because it is much more potent than tumor necrosis factor (TNFα) with respect to inducing cartilage destruction, requiring only 0.1–1.0% of the TNFα dose to achieve the same proteoglycan synthesis inhibition in chondrocytes. In joints, IL-1β is synthesized by chondrocytes, osteoblasts, synoviocytes and mononuclear cells and exerts its effect via binding to membrane receptor IL-1 receptor (IL-1R1), whereas binding to IL-1R2 forms an inactive ligand-receptor complex that is unable to activate the intracellular signal. Both, IL-1R1 and IL-1R2 also bind IL-1α and IL-1R antagonist (IL-1Ra). In OA, there are increased levels of IL-1β in the synovial fluid, synovial membrane, cartilage and the subchondral bone layer and, furthermore, the expression of IL-1R1 on the surface of chondrocytes and synoviocytes is also increased. Via activation of the transcription factors nuclear factor-kappa B (NF-κB), p38MAPK and c-Jun N-terminal kinase and their downstream signalling cascade, decreases the synthesis of key extracellular matrix (ECM) proteins in chondrocytes, such as collagen II and proteoglycans (e.g. aggrecan) and stimulates the production of matrix degrading proteases, such as matrix metalloproteinase 1 (MMP-1), MMP-3, MMP-13 and ADAMTS 4, a disintegrin and metalloproteinase with thrombospondin motifs 4. Furthermore IL-1β induces apoptosis in chondrocytes via upregulation of the Bcl-2 protein family members, mitochondrial depolarization, reactive oxygen species production and dysregulation of enzymatic antioxidant defenses in chondrocytes.

Damaged articular cartilage has little or no healing capacity because it is hypocellular, avascular, aneural and alymphatic, has a dense ECM that limits the migration capacity of the sparse population of chondrocytes, and has low metabolic activity. Hence, once damage has occurred, cartilage lesions are likely to progress.

Current treatment strategies are only symptom modifying, leaving a large unmet need for efficacious disease-modifying therapies, which has resulted in a growing interest in regenerative medicine approaches to OA. Based on our increasing understanding of the signalling pathways and key molecules interacting in the cascade of joint homeostasis and the pathophysiological processes involved in the development of OA, inflammatory mediators represent promising potential targets for therapeutic interventions designed to reduce both symptoms and structural joint damage in OA. Given the pivotal role of IL-1 as a pro-inflammatory cytokine in the development of OA, its natural opponent IL-1Ra has been investigated in OA treatment. In vitro and animal models of IL-1 inhibition by IL-1Ra showed a reduction of cartilage destruction associated with this therapy. Commercically available kits that produce autologous conditioned serum containing an upregulated higher amount of IL-1Ra compared to the concentration found in unprocessed blood samples are available for humans, horses and dogs. However, multiple joint injections are recommended to achieve clinically meaningful results. Therapeutic intervention to limit articular cartilage damage is likely most efficient early in disease progression when there is a possibility of preserving or re-establishing articular homeostasis and enabling anabolic activity to balance the catabolic pathways activated by inflammatory mediators. However, even in established OA, modulation of the articular microenvironment could significantly contribute to the treatment success.

Gene therapy is able to deliver a therapeutic gene to the target tissue ensuring a more constant and longer lasting therapeutic effect without the need of frequently repeated invasive articular injections. Gene therapy applications to treat OA or rheumatoid arthritis have been published showing promising results. To interfere with joint homeostasis only when needed, an adjustable gene therapy is an attractive approach for fine-tuning any potential genetic treatment. Inflammation inducible promoters have shown their great value in the context of tunable gene therapy. Such disease- (inflammation) responsive promoters will be ‘switched on’ only when pro-inflammatory cytokines are present, and will be silent again once the joint flap has been successfully treated. In these cases, stimulation of the regulatory elements to enhance transgene expression from the outside would not be needed as is the need with tetracycline responsive promoter systems. Indeed, the OA-affected joint would initiate the expression of the therapeutic gene and hence treatment when IL-1β and TNFα are upregulated in the stage of inflammation.

A combination of tissue engineering methods employing progenitor cells such as mesenchymal stem cells (MSCs) or induced pluripotent stem cells together with gene therapy highlights a novel approach for targeting OA and cartilage defects and the early data reveal promising results. Genetically manipulated MSCs employed in vitro and in vivo studies have shown their capacity to improve the quality of the repair tissue that would normally fill articular cartilage defects. MSC-based gene therapy approaches not only allow the delivery of a therapeutic gene (either anti-inflammatory or anabolic) to treat OA, but also open the possibility of delivering genes that enhance chondrogenesis such as TGF-β and hence promote the regenerative capacity of MSCs to fill the cartilage defect with a hyaline-like cartilage providing mechanical properties close to the natural healthy articular cartilage.

Recently, we have shown that equine MSCs can be efficiently transduced with lentiviral vector in which the firefly luciferase reporter gene was driven by an inflammation inducible promoter.
The present study aimed to investigate tunable IL-1Ra expression in equine MSCs using a composite, NF-κB-responsive enhancer/promoter regulated by the pro-inflammatory cytokines TNFα and IL-1β. Accordingly, a bicistronic lentiviral vector carrying the gene for equine IL-1Ra under the control of the inducible NFkB/minimal cytomegalovirus immediately early (minCMV) CMV promoter region was constructed and the ability to produce IL-1Ra via transduced equine MSCs stimulated with TNFα and IL-1β was determined. In addition, the biological activity and therapeutic effect of the IL-1Ra protein produced from transduced MSCs was analysed in vitro.

2 | MATERIALS AND METHODS

2.1 | Preparation and characterisation of IL-1Ra-expressing equine MSCs

Plasmid pAlli10-target1916 harbouring the coding sequence of the equine IL-1Ra gene (GenBank accession number U92482) under the control of synthetic NF-κB-responsive promoter identical to the one used in our previous work was custom-synthesized by Trenzyme (Konstanz, Germany). To obtain vector plasmid pSEWNFkBIL-1Ra, a 753-bp EcoRI-EcoRI fragment containing the NF-κB-responsive elements, the minimal CMV promoter and the equine IL-1Ra gene was isolated from pAlli10-target1916 plasmid and inserted into the lentiviral vector plasmid pHRSIN2-SEW linearized using EcoRI. Recombinant lentivirus particles were produced and the respective titre was estimated as described previously.

MSCs were isolated from bone marrow collected from the iliac crest of a 3-year-old male horse euthanized for reasons not related to the present study. MSCs were cultured as described previously. MSCs were collected in accordance with the ‘Good Scientific Practice. Ethics in Science and Research’ regulation implemented at the University of Veterinary Medicine Vienna. The animal owner’s consent to collect and analyse the material and to publish resulting data was obtained in accordance with the standard procedures of the University of Veterinary Medicine Vienna.

To obtain SEWNFkBIL-1Ra-transduced MSCs (MSC/IL-1Ra), cells in passage 4 were transduced with virus vector supernatant at a multiplicity of infection (MOI) of 6 in the presence of 8 μg/ml polybrene. Transduction efficiency was determined by counting the number of enhanced green fluorescent protein (EGFP) expressing cells using fluorescence-activated cell sorting (FACS) analysis. Additionally, the number of EGFP copies in the genomic DNA (corresponding to the number of provirus integration events) was quantified by quantitative polymerase chain reaction (PCR). Accordingly, DNA was isolated utilizing the DNeasy Blood & Tissue Kit (Qiagen, Valencia, CA, USA) in accordance with the recommended protocol for cultured cells. EGFP copy numbers were determined by quantitative PCR (qPCR) using a gene specific TaqMan probe assay as described previously. Quantitative PCR was carried out on the AriaMx Realtime PCR System (Agilent Technologies Inc., Santa Clara, CA, USA) using 25-μl reaction mixes, including 20 ng of DNA template, 0.2 mM each dNTP, 3 mM MgCl2, 1 x buffer B2 (Solis BioDyne, Tartu, Estonia), 300 nM each primer, 200 nM probe, 50 nM ROX reference dye (Biotium, Freemont, CA, USA) and 1 unit of HOT FIREPol DNA polymerase (Solis BioDyne). After initial denaturation at 95°C for 10 min, 45 amplification cycles of 95°C for 15 s and 60°C for 1 min were performed. A standard dilution series made of EGFP-containing plasmid DNA was included to determine EGFP copy numbers, as described previously. EGFP copy numbers per cell were calculated, assuming a DNA content of 6.6 pg per one mammalian cell.

2.2 | Analysis of IL-1Ra protein production in transduced equine MSCs

To test the inducibility of IL-1Ra production, MSC/IL-1Ra cells were seeded at densities of 3 × 10^3 and 6 × 10^3 cells/well of a 96-well plate. Two different cell densities were tested with regard to the planed short term (IL-1Ra induction, decline after cytokine withdrawal) and long term (repeated induction) experiments (see below). Twenty-four hours later, cells were stimulated with different concentrations (0.1, 1, 5 and 10 ng/ml) of recombinant human IL-1β or recombinant human TNFα (both ImmunoTools, Friesoythe, Germany) for 48 h based on the results of previous work using a vector design similar to that employed in the present study. The IL-1Ra protein concentration was measured in the cell supernatant using the RayBio Equine IL-1Ra enzyme-linked immunosorbent assay (ELISA) Kit (RayBiotech, Inc., Norcross, GA, USA) in accordance with the manufacturer’s recommendations and the Infinite M200 Pro plate reader (Tecan, Männedorf, Switzerland). Relative IL-1Ra production was calculated as fold increase of stimulated cells compared to nonstimulated cells. To correlate the IL-1Ra protein production with the cell amount seeded, cells were counted using Trypan Blue Stain 0.4% (Molecular Probes, Carlsbad, CA, USA) in a COUNTERS Automated Cell Counter (Invitrogen, Carlsbad, CA, USA) at the time of supernatant harvesting and the IL-1Ra protein production from 10 000 cells within 48 h was calculated (normalized production).

For analysis of IL-1Ra decline after cytokine withdrawal, 6 × 10^3 MSC/IL-1Ra cells were seeded per well into a 96-well plate. After 24 h, cells were stimulated with 10 ng/ml TNFα for 48 h and, subsequently, the medium was changed every day. After 2, 4 and 6 days, the IL-1Ra protein concentration was measured and relative IL-1Ra production was calculated as described above.

For repeated induction experiments, 3 × 10^3 MSC/IL-1Ra cells were seeded per well of a 96-well plate and stimulated after 24 h with 10 ng/ml TNFα: first stimulation for 48 h – 144 h off-cytokine (first drop-down) – second stimulation for 48 h – 144 h off-cytokine (second drop-down). At all indicated time points, the IL-1Ra protein concentration was measured and relative IL-1Ra production was calculated as described above. All experiments were performed in duplicate with at least two independent experimental replicates.

2.3 | Analysis of IL-1Ra gene expression in transduced equine MSCs

IL-1Ra gene expression was analysed using real-time q-PCR (RT-qPCR). Therefore, the MSC/IL-1Ra cells were seeded at a density of 1.4 × 10^5 cells/well in the six-well plate. Twenty-four hours later, cells were stimulated with 10 ng/ml TNFα for 48 h and, subsequently, the medium was changed every day. At the indicated time points
(stimulation for 48 h followed by cytokine withdrawal for 24, 48, 72, 96, 120, 144 and 168 h), cells were harvested using 500 μl of Qiazol lysis reagent (Qiagen) and stored at -80°C until further processing. RNA extraction was performed using the Direct-zol RNA Miniprep Kit (Zymo Research, Irvine, CA, USA) in accordance with the manufacturer’s instructions. Controls without RT enzyme were included to monitor for PCR amplification of residual DNA.

Chondrocytes spheroids were mechanically homogenised on a MagNA Lyser instrument (Roche, Basel, Switzerland) using 1.4-mm ceramic beads at 6500 rpm for 25 s prior to RNA extraction. RNA concentrations were measured on the NanoDrop 2000c UV spectrophotometer (Thermo Scientific, Waltham, MA, USA). The RNA integrity of selected samples was assessed on the Agilent 2100 Bioanalyzer using the RNA 6000 Nano Kit (Agilent Technologies Inc.). The determined RNA integrity numbers ranged from 9.1 to 10. For RT-qPCR, 1 μg of total RNA was transcribed into cDNA using the High Capacity cDNA Reverse Transcription Kit (Thermo Scientific) in accordance with the manufacturer’s instructions. Controls without RT enzyme were included to monitor for PCR amplification of residual DNA. RT-qPCR primer were designed using the PrimerQuest assay design tool (http://eu.idtdna.com/PrimerQuest/Home/Index; Integrated DNA Technologies, Coralville, IA, USA) or taken from the literature.60,61 Assay details are provided in Table 1. All assays were validated by the generation of standard curves for determining PCR reactions efficiencies (Table 1). RT-qPCR was performed in 20-μl reaction volumes including 20 ng of cDNA, 200 nM each primer and 1 × Kapa Sybr Fast qPCR Master Mix ROX Low (Kapa Biosystems, Wilmington, MA, USA). All samples were analysed in duplicate on the AriaMx Realtime PCR System (Agilent Technologies Inc.) using the temperatures: initial denaturation at 95°C for 3 min, followed by 40 cycles of 95°C for 3 s and 60°C for 20 s, and a melting curve analysis over a temperature range of 65°C to 95°C. Four candidate reference genes (RGs) GAPDH, REEP5, SNRPD3 and VCP were included for normalization.61 The expression stability of all RGs was assessed using the BestKeeper analysis tool,62 identifying VCP as the most stable gene [SD (±Cq) VCP: 0.44, REEP5: 0.55, GAPDH: 0.57, SNRPD3: 0.66]. Target gene expression levels were normalized to those of VCP and relative expression changes were calculated using the comparative 2−ΔΔCT method.63

### Table 1: Primer used for RT-qPCR

| Accession number* | Gene symbol | Gene name | Oligo | Sequence (5′ to 3′) | Amplicon size (bp) | PCR efficiency (%) | Reference |
|-------------------|-------------|-----------|-------|---------------------|--------------------|-------------------|-----------|
| XM_004733894.1, XM_00562799.1 | ACAN | Equus caballus aggrecan | Forward | CCGTACTACGGCGTTATC | 99 | 0.952 | – |
| | | | Reverse | CCGTGGACCCATCTTCATC | – | – | – |
| NM_001081764.1, XM_005611082.2 | COL2A1 | Equus caballus collagen type II alpha 1 chain | Forward | GCCCGCTGGTCTTGTGAACT | 91 | 0.932 | – |
| | | | Reverse | CGTGACGGGAGTGGGAATG | – | – | – |
| NM_001163856.1 | GAPDH | Equus caballus glyceraldehyde-3-phosphate dehydrogenase | Forward | GCCAAATGTATGCCACAGT | 129 | 0.904 | 61 |
| | | | Reverse | CCCACATATACCGACAGCAT | – | – | – |
| NM_001317261.1, XM_001495926.4 | IL1B | Equus caballus interleukin 1 beta | Forward | GGTGTCAAGGAAAGAACT | 175 | 0.924 | 60 |
| | | | Reverse | GGGGTACTTGGCACACTCA | – | – | – |
| NM_0014730883.1, XM_005599766.2 | IL1RN | Equus caballus interleukin 1 receptor antagon | Forward | GACACCTAATCTCTCCTCCTCCT | 95 | 0.997 | – |
| | | | Reverse | GATTCTGAAGGCTTGCATCTTG | – | – | – |
| NM_001082496.2 | IL6 | Equus caballus interleukin 6 | Forward | CAAGCACCCTCAGCCATGTGCC | 90 | 0.944 | – |
| | | | Reverse | CATCTTTCTGCAGTGTTGG | – | – | – |
| NM_001083951.2 | IL8 | Equus caballus C-X-C motif chemokine ligand 8 | Forward | TGCTTTTGAGCTCTGTTG | 181 | 0.949 | – |
| | | | Reverse | GCTCCGGTGACGGCTTCC | – | – | – |
| NM_001081847.2 | MMP1 | Equus caballus matrix metalloproteinase 1 | Forward | CCGAAGGGCACTCCTGCTT | 93 | 0.919 | 60 |
| | | | Reverse | TGGCCCTGTCACACACCTG | – | – | – |
| NM_001082495.2 | MMP3 | Equus caballus matrix metalloproteinase 3 | Forward | GCACAGGGAAGGCTGATAAAGC | 91 | 0.914 | – |
| | | | Reverse | CAAGGATAGGCGTGAGCCACGC | – | – | – |
| NM_001081804.1 | MMP13 | Equus caballus matrix metalloproteinase 13 | Forward | GCCCTTCAAAGGTTGCTGATT | 109 | 0.914 | – |
| | | | Reverse | GGGTAAAAAGCTTGCTGATTG | – | – | – |
| NM_001081935.1, XM_014735868.1, XM_014735869.1, XM_005599722.1 | PTGES | Equus caballus prostaglandin E synthase | Forward | CGCTCCTGAAGGCTGTTAAT | 83 | 0.932 | – |
| | | | Reverse | CAGATACGAGGACCACTGGA | – | – | – |
| XM_001489060.4 | SNRPD3 | Equus caballus small nuclear ribonucleoprotein D3 polypeptide | Forward | AGCAACCTCTTTGAAAGAGGCTG | 120 | 0.995 | 61 |
| | | | Reverse | GACCACCCCTTTCATTCCACGT | – | – | – |
| NM_001081819.2, XM_005603490.1 | TNF | Equus caballus tumor necrosis factor | Forward | TTCTGAACCCCAAAGTACAAG | 65 | 0.927 | 60 |
| | | | Reverse | GCTGCCCCCTCCGCTT | – | – | – |
| XM_005605574.1 | VCP | Equus caballus valosin containing protein | Forward | GAGTGAGATCAGGCGAGAACG | 56 | 0.925 | 61 |

*National Center for Biotechnology Information (NCBI), Entrez Gene (http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene).
2.4 Cytokine-induction of OA-like processes in equine chondrocytes in vitro

To isolate equine chondrocytes, articular cartilage of a 4-year-old horse euthanized for reason unrelated to the presented research topic was obtained by dissection, cut into small pieces and processed as described previously. Isolated chondrocytes were cultivated in cell culture medium consisting of Dulbecco’s modified Eagle’s medium low glucose/Ham’s F12 (1:1), supplemented with 10% fetal bovine serum, antibiotic/antimycotic mix solution (100 000 units penicillin, 100 mg of streptomycin and 250 μg of amphotericin B per litre medium) and an additional 1.25 μg/ml amphotericin B (chondrocyte medium; all chemicals purchased from Sigma, St Louis, MO, USA). Cells were frozen after first passage and used in the experiments no later than in passage 3.

To set up the two-dimensional (2D) OA in vitro model, 2 × 10⁵ equine chondrocytes per well were seeded in a six-well plate and grew in a monolayer. Forty-eight hours later, culture medium was changed to a fresh one containing either IL-1β or TNFα at a concentration of 5, 10 or 50 ng/ml. After 24, 48 and 72 h, cells were harvested using QIAzol lysis reagent and subjected to RT-qPCR as described above. The expression pattern of the following OA-related genes was analysed: aggrecan (ACAN), collagen IIA1 (COL2A1), IL-6, MMP1, MMP3, MMP13, TNFα, prostaglandin-E2 synthase (PTGES) (Table 1). Expression patterns (target genes normalised to VCP) of cytokine TNFα using RT-qPCR of MMP1, MMP13, ACAN, COL2A1; normalised to VCP) was analysed: aggrecan (ACAN), collagen IIA1 (COL2A1), IL-6 (IL-6, MMP1, MMP3, MMP13, TNFα, prostaglandin-E2 synthase (PTGES) (Table 1). Expression patterns (target genes normalised to VCP) of cytokine-treated cells were compared with mRNA expression in nontreated cells set to 1.

To set up the three-dimensional (3D) OA in vitro model, 5 × 10⁵ equine chondrocytes per Eppendorf Tube were centrifuged (200 x g for 1 min at room temperature) and allowed to form spheroids within 24 h of cultivation. Afterwards, four to six spheroids were transferred per well of a six-well plate and incubated in fresh medium containing either IL-1β, TNFα or a combination of both (10 ng/ml). After 24, 48 and 72 h, the expression pattern of OA-related genes (IL-6, IL-8, MMP1, MMP3, MMP13, ACAN, COL2A1; normalised to VCP) was analysed using RT-qPCR as described above and cytokine-treated spheroids were compared with mRNA expression of nontreated spheroids arbitrarily set to 1.

2.5 Application of conditioned medium produced from MSC/IL-1Ra cells

To evaluate the biological activity of the produced IL-1Ra protein, conditioned medium from MSC/IL1Ra cells was tested in the 2D OA in vitro model. To produce conditioned medium, MSC/IL-1Ra cells were seeded at a concentration of 1.5 × 10⁶ cells per T75 flask and stimulated with 10 ng/ml TNFα 24 h later or left unstimulated. After 48 h of stimulation, medium was changed for a fresh one without cytokine. Twenty-four hours later, conditioned medium was harvested and centrifuged (600 x g for 5 min at room temperature) to avoid cell carry-over. To exclude the possibility that effects are related to other factors produced from MSCs, conditioned medium of stimulated and unstimulated nontransduced MSCs was produced accordingly. Conditioned media were applied to chondrocytes (2 × 10⁵ cells/well of the six-well plate seeded 48 h earlier) concomitantly with 10 ng/ml IL-1β.

In a second approach, chondrocytes were pre-treated with conditioned medium for 24 h and subsequently treated with 10 ng/ml IL-1β. After 24 h, RT-qPCR analysis of ACAN, COL2A1, IL-6, IL-8, MMP1 and MMP13 was performed as described above. Chondrocytes cultured in MSC medium containing IL-1β for OA induction were used as controls and mRNA levels obtained in these cells were arbitrarily set to 1.

2.6 Co-cultivation of MSC/IL-1Ra cells with osteoarthritic chondrocytes

To model a therapeutic approach, MSC/IL-Ra cells were co-cultured with osteoarthritic chondrocyte spheroids (3D OA model). Therefore, spheroids were prepared as described above, transferred to a six-well plate, and OA was induced by adding either IL-1β or TNFα, or a combination of both (10 ng/ml). After 24 h of OA induction, transwell inserts containing MSC/IL-Ra cells [seeded separately 24 h earlier at the concentration of 1 × 10⁵ cells/insert (0.4 μm pore size, polycarbonate membrane)] were added to the chondrocytes. Without a change of medium (i.e. in the presence of the cytokines mentioned above), chondrocyte spheroids were co-cultivated with MSC/IL-Ra cells for an additional 24, 48 or 72 h when RT-qPCR analysis of ACAN, COL2A1, IL-6, IL-8, MMP1 and MMP13 was performed as described above. Chondrocyte spheroids grown in the absence of MSC/IL-Ra cells but treated with the respective cytokines for OA induction were used as controls and their mRNA levels were arbitrarily set to 1.

2.7 Statistical analysis

For statistical analysis of the IL-1RA protein concentration measured via ELISA, as well as mRNA expression of OA-related genes assessed by RT-qPCR, the results of the respective control groups were arbitrary set to 1 and a relative increase or decrease was computed (as the fold change). Mean values and 95% confidence intervals were calculated from the technical replicates. Lower confidence limits greater than 1 (i.e. increase) and upper confidence limits less than 1 (i.e. decrease) were assumed to be significant.

3 RESULTS

3.1 Preparation and characterisation of IL-1Ra-expressing equine MSCs

Upon successful isolation from bone marrow, MSCs were transduced with the lentivirus vector SEWNFkBIL-1Ra. In this vector, IL-1Ra expression in transduced cells is driven by the inducible NF-xB/ minCMV promoter, whereas EGFP expression is ensured from the constitutively active SFFV promoter. A single round of transfection using VSV-G (i.e. vesicular stomatitis virus G-protein) pseudotyped SEWNFkBIL-1Ra vector particles at a MOI of 6 resulted in more than 90% transduced cells (MSC/IL-1Ra), as determined by EGFP-specific FACS analysis. The qPCR revealed 1.06 ± 0.07 EGFP copies per cell, resulting statistically in one integrated provirus molecule per transduced MSC.
3.2 | Induction of IL-1Ra expression in transduced equine MSCs

Inducibility of the IL-1Ra protein production was measured in the supernatant of MSC/IL-1Ra cells stimulated for 48 h with different concentrations of IL-1β or TNFα using species-specific ELISA. In nonstimulated MSC/IL-1Ra cells, basal IL-1Ra protein levels (7.3 and 13.9 ng/ml/48 h for 3 × 10³ and 6 × 10³ cells seeded) were detected as a result of the presence of minimal CMV promoter sequences in the synthetic NF-kB-inducible promoter. As expected, TNFα induced IL-1Ra protein expression in a dose-dependent manner (Figure 1A). An up to five-fold increase in IL-1Ra production was observed in cells stimulated with 10 ng/ml TNFα. Interestingly, no changes in IL-1Ra protein production were observed upon IL-1β stimulation (Figure 1A). Therefore, the subsequent induction experiments were performed using TNFα only. The cell seeding density influenced the absolute IL-1Ra protein production over the definite period of time; however, the relative changes (fold-changes) remained constant irrespective of the cell amount seeded (Figure 1A). In non-infected, parental MSCs, no IL-1Ra protein was detected. The IL-1Ra protein production per 10⁵ cells was similar irrespective of the initial seeding density (Figure 1B). In 48 h, nonstimulated cells produced approximately 1 ng/ml IL-1Ra protein, and protein concentration was increased to approximately 4 ng/ml in cells stimulated with 10 ng/ml TNFα (Figure 1B).

In the next step, we analysed the repeated inducibility of IL-1Ra expression from MSC/IL-1Ra cells. However, use of the same experimental set-up as that employed in our previous work (48 h of induction followed by 48 h of off-stimulation) was not sufficient to bring the IL-1Ra protein levels back to those observed in nonstimulated MSC/IL-1Ra cells. Accordingly, we analysed the decline of the IL-1Ra expression over time in stimulated MSC/IL-1Ra cells both at mRNA and protein levels. Upon stimulation with 10 ng/ml TNFα for 48 h, IL-1Ra mRNA levels in stimulated cells were significantly higher (approximately 9.5-fold) compared to nonstimulated cells (Figure 2A). IL-1Ra mRNA expression continuously decreased over the following days, reaching the basal level between days 4 and 7 after TNFα withdrawal (Figure 2A). Similarly, IL-1Ra protein production in MSC/IL-Ra cells stimulated with 10 ng/ml TNFα declined in the absence of TNFα stimulus over time (Figure 2B).

Protein levels returned to baseline at day 6 after cytokine withdrawal (Figure 2B). Therefore, 6 days without cytokine stimulation was considered sufficient for the repeated stimulation experiment.

Finally, MSC/IL-1Ra cells were repeatedly stimulated with 10 ng/ml TNFα (stimulation for 48 h – 144 h withdrawal of cytokine – second stimulation for 48 h – second 144 h withdrawal of cytokine). After the first stimulation, the IL-1Ra protein levels were increased six- to seven-fold followed by a regression to 1-1Ra protein levels after 6 days of cultivation without TNFα (Figure 2C). Repeated stimulation also yielded a statistically significant three-fold increase in IL-1Ra protein production. Another 6 days without the cytokine stimulus resulted in IL-1Ra protein basal levels again (Figure 2C).

3.3 | 2D osteoarthritis in vitro model

In the 2D OA in vitro model, the expression pattern of ten OA-related genes (IL-1β, IL-6, IL-8, TNFα, MMP1, MMP3, MMP13, COL2A1, ACAN, PTGES) of equine chondrocytes was analysed after IL-1β or TNFα stimulation (Figure 3; see also Supporting information, Figure S1). Compared to nontreated cells, mRNA expression of ACAN and COL2A1 was statistically significant decreased after both IL-1β or TNFα treatment, with a higher cytokine concentration and longer stimulation producing stronger effects. IL-6, IL-8, MMP1 and MMP13 mRNA levels were significantly increased upon cytokine treatment, with the strongest effects being observed after 24 h of stimulation. Only a marginal increase of mRNA levels was observed in the case of PTGES, with changes in IL-1β, TNFα, and MMP3 mRNA levels being less obvious and inconsistent (see Supporting information, Figure S1). Based on these observations, analysis of ACAN, COL2A1, IL-6, IL-8, MMP1 and MMP13 mRNA levels and treatment with the respective cytokine(s) (10 ng/ml) was chosen for further experiments to monitor osteoarthritic changes in further experiments using OA in vitro models.

3.4 | Application of conditioned medium produced from MSC/IL-1Ra cells

To evaluate the biological activity of the IL-1Ra protein produced by the genetically modified MSCs, conditioned medium from these cells was
tested in the 2D OA in vitro model and mRNA levels of ACAN, COL2A1, IL-6, IL-8, MMP1 and MMP13 were analysed (Figure 4; see also Supporting information, Figure S2). To exclude the possibility that the effects are related to other factors produced from MSCs, conditioned medium of nontransduced MSCs was used as a control. Application of 24-h conditioned medium of stimulated and nonstimulated MSC/IL-1Ra cells together with 10 ng/ml IL-1β resulted in a 2.5-fold increase of ACAN mRNA levels, whereas only minor changes were observed in COL2A1 expression levels (Figure 4). Furthermore, chondrocytes treated with conditioned medium from stimulated and nonstimulated, nontransduced MSCs resulted in unchanged expression levels of ACAN but revealed up-regulation of IL-6, IL-8 and MMP1 compared to control chondrocytes with OA phenotype. Only marginal differences were observed between conditioned medium from stimulated and nonstimulated naïve MSCs as well as MSC/IL-1Ra cells. Similar changes in gene expression for ACAN, COL2A1, MMP1 and MMP13 were obtained when chondrocytes were pre-treated with the conditioned medium and the OA-changes were induced 24 h later; however, up-regulation of IL-6 and IL-8 was not seen (Supporting information, Figure S2).

3.5 | 3D osteoarthritis in vitro model

To better mimic the natural situation, chondrocytes were grown in spheroids. For this 3D OA in vitro model, compact spheroids were formed within 24 h after a single centrifugation step and cultivation of cells on a non-adherent surface. Pre-formed spheroids were subjected to cytokine treatment and mRNA expression of ACAN, COL2A1, IL-6, IL-8, MMP1 and MMP13 genes was analysed (Figure 5). Generally, changes in mRNA expression were stronger in the 3D OA model compared to the 2D OA model. Stronger effects were produced by combined treatment (IL-1β + TNFα) and longer stimulation (24 h versus 72 h). As expected, matrix related gene expression was reduced by approximately 60% (ACAN) and 90% (COL2A1) in cytokine-treated spheroids, whereas expression of pro-inflammatory cytokines (IL-6, IL-8) and matrix-degrading proteases (MMP1, MMP13) was increased by up to 400-fold (Figure 5). Based on these results, 24 h of cytokine treatment was considered to be sufficient for OA induction in the 3D in vitro model.

3.6 | Co-cultivation of MSC/IL-1Ra cells with osteoarthritic chondrocytes

To model a therapeutic approach, OA-induced chondrocyte spheroids were co-cultured with MSC/IL-1Ra cells in the presence of pro-inflammatory cytokines (IL-1β, TNFα or a combination of both). Expression levels of ACAN, COL2A1, IL-6, IL-8, MMP1 and MMP13 were compared with those of osteoarthritic chondrocytes grown in the absence of MSC/IL-1Ra cells (Figure 6). The mRNA levels of ACAN and COL2A1 genes were significantly increased. A significant
decrease in IL-6, MMP1 and MMP13 expression levels was observed in co-cultured chondrocytes, whereas the changes in IL-8 mRNA levels were less obvious and inconsistent. These effects were most distinct after OA induction with IL-1β and less prominent after treatment with TNFα and the combination of IL-1β and TNFα.

4 | DISCUSSION

As a result of the limited self-renewal capacity of adult articular cartilage, cartilage defects and osteoarthritis lead to intense investigation on clinically applicable cartilage regenerating techniques.65 MSCs represent an interesting cell source for cartilage repair because of their multilevel action (mostly paracrine activity, organelle and molecule transfer via tunnelling nanotubes, exosome and microvesicle transfer of molecules, as well as marginally also differentiation into replacement cell type)66-68 and several preclinical and clinical trials have provided initial evidence of their efficacy and safety in the treatment of OA.69,70 However, MSCs have a tendency to undergo hypertrophic differentiation and, when exposed to an inflammatory environment, they show a reduced chondrogenic differentiation capacity.71-74 Hence intra-articular application of MSCs has not yet achieved full restoration of hyaline cartilage. Employing the gene therapy concept to increase cartilage regeneration by expression of specific genes (e.g. anti-inflammatory cytokines, growth and transcription factors) represents another promising therapeutic strategy.75 Combining cellular therapy using MSCs with gene transfer can combine the advantages of both innovating strategies and might help to overcome challenges that arise from using naïve MSCs. However, when using gene transfer techniques resulting in host genome
integration of the therapeutic cargo, which is usually necessary for persisting gene transfer, concerns associated with genotoxicity and mutagenic effects have to be considered. To minimize this risk, we have used the third generation lentivirus vector system. These vectors, which are well characterized with the existing regulatory framework to achieve its successful translation into the clinical stage, were recently used for gene addition to haematopoietic stem cells and have yielded clinical benefits without vector-related complications.\textsuperscript{76,77}

Controllable and tunable transgene expression is highly desirable to maintain joint homeostasis. We have previously shown that equine MSCs can be efficiently transduced with a lentiviral vector harbouring a reporter gene under the control of an inflammation inducible promoter and the transgene expression can be induced by pro-inflammatory cytokines IL-1β or TNFα.\textsuperscript{49} To further elaborate this strategy in the present study, we have analysed the feasibility of a biological active MSC-based gene therapy in an in vitro model of OA.

The gene encoding the IL-1Ra protein was chosen as therapeutic gene because it was shown that administration of IL-1Ra (either recombinant or present in autologous conditioned serum) is efficient in the treatment of cartilage degeneration in OA.\textsuperscript{78-80} Furthermore, gene therapy approaches utilizing virus-mediated transfer of the IL-1Ra gene into chondrocytes in vitro and in vivo revealed therapeutic potential.\textsuperscript{81-83}

IL-1Ra expression was increased by up to five-fold in MSC/IL-1Ra cells stimulated with TNFα, which is in line with our data based on transduced MSCs with NF-kB-inducible luciferase expression (MSC/Luc) using the same NF-kB-promoter reported previously.\textsuperscript{49} Upon IL-1β stimulation, no changes in IL-1Ra protein production were observed compared to baseline levels. Because, in our previous study, both cytokines induced luciferase expression in MSC/Luc cells in a dose-dependent manner, we presume that baseline IL-1Ra protein production from MSC/IL-1Ra cells occupies the IL-1β receptor, blocks IL-1β binding and prevents promoter induction. Therefore, the IL-1Ra protein expression levels following IL-1β stimulation remain similar to those measured in nonstimulated MSC/IL-RA cells. This finding represents the first proof of biological activity of the expressed transgene.

Transgene expression was also detected in nonstimulated MSC/IL-1Ra cells as a result of the presence of the minimal CMV promoter sequence within the inducible promoter, which is in agreement with our previous observations,\textsuperscript{49} as well as with the observations of other studies.\textsuperscript{84} The concentration of IL-1Ra protein produced from nonstimulated MSC/IL-1Ra cells (1.2 ng/ml/10 000 cells/48 h) is within the range of IL-1Ra levels in autologous conditioned serum.\textsuperscript{39,85} The use of tightly regulated inducible promoters such as those described recently by Mohamed et al.\textsuperscript{50} might increase the specificity of expression.

Surprisingly, the decrease in IL-1Ra expression in MSC/IL-1Ra cells after TNFα withdrawal was three times slower (both on mRNA and protein levels) than the drop in luciferase expression previously observed in MSC/Luc cells,\textsuperscript{49} probably as a result of the short half-life
of luciferase of less than 4 h. Repeated stimulation of IL-1Ra production was possible, although IL-1Ra levels after the second stimulation were reduced to 50% compared to the first one. This is in accordance with our observations using luciferase expressing MSCs. An in vitro model of osteoarthritis was used to study the therapeutic potential of MSC/IL-1Ra cells further. Cytokine addition to the culture medium has been shown to produce OA-like changes in chondrocytes (altered OA-relevant gene expression) and therefore represents a well-established in vitro model and evaluation tool in experimental OA therapy research. Because isolated chondrocytes are prone to dedifferentiation in 2D culture and redifferentiate in 3D culture, we performed all experiments with cells in low passage number (< passage 3) and carried out experiments in 2D and 3D culture to determine the chondrogenic phenotype of the chondrocytes. Because the data in the literature differ with respect to cytokine concentration and the duration of treatment, we first analysed the effect of cytokine concentrations and combination of cytokines over 72 h on target gene expression in chondrocytes cultured in 2D and 3D. For further experiments, a cytokine concentration of 10 ng/ml was chosen because it produced distinct alteration in gene expression and is pathophysiologically relevant. Inflammation-induced osteoarthritic changes were most apparent after 24 h of cytokine treatment, which is in agreement with the results reported by Rai et al. Furthermore, changes in gene expression were more pronounced in the 3D OA model than those measured in the 2D OA model. Biological activity of the produced recombinant molecule was further demonstrated by the protective effect of conditioned medium from MSC/IL-1Ra cells blocking the OA onset in cytokine-treated chondrocytes. Basal IL-1Ra protein levels obtained in nonstimulated MSC/IL-1Ra cells were sufficient to exert this effect. Conditioned medium from nontransduced MSC had no protective effect and,
instead, the contrary effect was observed, because chondrocytes treated with conditioned medium from stimulated and nonstimulated, nontransduced MSC revealed up-regulation of IL-6, IL-8 and MMP1, as well as down-regulation of COL2A1 genes. These observations were fairly unexpected because it is known that MSCs secrete factors inhibiting inflammatory processes and a protective effect of MSC co-cultivated with IL-1β-treated chondrocytes in a rat osteoarthritic model was reported recently. We are aware that these expression changes are influenced by several parameters that are closely related to the experimental set-up (e.g. co-cultivation versus conditioned medium, timing and duration of cytokine treatment, cell cultivation and harvesting time for RNA analysis), which might differ among the research groups and publications. Therefore, any direct comparison might be difficult. Co-cultivation of MSC/IL-1Ra cells with osteoarthritic spheroids alleviated the severity of osteoarthritic changes and this effect was most distinct after OA induction with IL-1β. This is not surprising because IL-1β is one of the key arthritogenic triggers and is much more potent than TNFα with respect to inducing cartilage destruction.

In conclusion, we could repeatedly induce transgene expression via cytokine stimulation of MSC/IL-1Ra cells. The IL-1Ra that was produced was biological active. Furthermore, we were able to demonstrate the protective ability of the IL-1Ra protein in an in vitro OA model analysing the genes responsible for extracellular matrix proteins, the enzymes for matrix degradation and pro-inflammatory cytokines. Future studies are planned that focus on an improvement of tight regulation of transgene expression and an assessment of the therapeutic potential of the described system in a relevant in vivo model.

**ACKNOWLEDGEMENTS**

We thank I. Ribitsch for providing the MSCs and J. Rosser for helping isolate the chondrocytes. We are grateful to A. Tichy and Z. Tonar for

---

**FIGURE 6** Co-cultivation of MSC/IL-1Ra cells with osteoarthritic spheroids alleviates the severity of the osteoarthritic changes. Using a transwell system, OA-induced chondrocyte spheroids were co-cultured with MSC/IL-1Ra cells in the presence of 10 ng/ml IL-1β or TNFα, or a combination of both, for 24, 48 and 72 hours. The mRNA levels of aggrecan, collagen IIα1, interleukin-6, interleukin-8, matrix metalloproteinase-1 and matrix metalloproteinase-13 were measured using RT-qPCR. Relative changes in mRNA levels of cytokine-treated, co-cultured chondrocytes are shown compared to cytokine-treated chondrocyte spheroids grown in the absence of MSC/IL-1Ra cells, arbitrary set to 1. Lower confidence limits greater than 1 and upper confidence limits less than 1 were assumed as statistically significant (*). Data show mean values; whiskers represent 95% confidence intervals.
statistical advice. This work was supported by the Bright Sparks Funding (PP10014701), Vetmeduni Vienna, Austria. SG, ME and JH designed the research study. SG, RE, KV and JH performed the research. SG, RE and JH analysed the data. All co-authors contributed to the preparation of the manuscript. The authors declare that they have no conflicts of interest.

ORCID

Reinhard Ertl © http://orcid.org/0000-0001-7485-3661
Juraj Hlavaty © http://orcid.org/0000-0003-3050-5176

REFERENCES

1. Kandahari AM, Yang X, Dighe AS, Pan D, Cui Q. Recognition of immune response for the early diagnosis and treatment of osteoarthritis. J Immunol Res. 2015;2015:192415.
2. Yu SP, Hunter DJ. Intra-articular therapies for osteoarthritis. Expert Opin Pharmacother. 2016;17:2057-2071.
3. Bora FW, Miller GW. Joint physiology, cartilage metabolism, and the etiology of osteoarthritis. Hand Clin. 1987;3:325-336.
4. Clarke SP, Mellor D, Clements DN, et al. Prevalence of radiographic signs of degenerative joint disease in a hospital population of cats. Vet Rec. 2005;157:793-799.
5. Clements DN, Fitzpatrick N, Carter SD, Day PJR. Cartilage gene expression correlates with radiographic severity of canine elbow osteoarthritis. Vet J. 2009;179:211-218.
6. Ireland JL, Wyllie CE, Collins SN, Verheyen KL, Newton JR. Preventive health care and owner-reported disease prevalence of horses and ponies in Great Britain. Res Vet Sci. 2013;95:418-424.
7. Vandeweerd JM, Hontoir F, Kirschvink N, et al. Prevalence of naturally occurring cartilage defects in the ovine knee. Osteoarthritis Cartilage. 2013;21:1125-1131.
8. Madry H, Cucchiari M. Gene therapy for human osteoarthritis: principles and clinical translation. Expert Opin Biol Ther. 2016;16:331-346.
9. Goldring MB. The role of cytokines as inflammatory mediators in osteoarthritis: lessons from animal models. Connect Tissue Res. 1999;40:1-11.
10. Haringman JJ, Ludikhuize J, Tak PP. Chemokines in joint disease: the key to inflammation? Ann Rheum Dis. 2004;63:1186-1194.
11. Hunter DJ. Are there promising biologic therapies for osteoarthritis? Curr Rheumatol Rep. 2008;10:19-25.
12. Sandell LJ, Xing X, Franz C, Davies S, Chang LW, Patra D. Exuberant expression of chemokine genes by adult human articular chondrocytes in response to IL-1beta. Osteoarthritis Cartilage. 2008;16:1560-1571.
13. Malemud CJ. Anticytokine therapy for osteoarthritis: evidence to date. Drugs Aging. 2010;27:95-115.
14. Wojdasiewicz P, Poniatowski ŁA, Szukiewicz D. The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis. Mediators Inflamm. 2014;2014:561459.
15. Goldring ML. Anticytokine therapy for osteoarthritis. Expert Opin Biol Ther. 2001;1:817-829.
16. Farahat MN, Yanni G, Poston R, Panayi GS. Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Ann Rheum Dis. 1993;52:870-875.
17. Symons JA, Young PR, Duff GW. Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist. Proc Natl Acad Sci U S A. 1995;92:1714-1718.
18. de Lange-Brokaar BJ, Ioan-Facsinay A, van Osch GJ, et al. Synovial inflammation, immune cells and their cytokines in osteoarthritis: a review. Osteoarthritis Cartilage. 2012;20:1484-1499.
19. Torrero JL, Martinez C. New developments in the treatment of osteoarthritis - focus on biologic agents. Open Access Rheumatol. 2015;7:33-43.
20. Martel-Pelletier J, McCollum R, DiBattista J, et al. The interleukin-1 receptor in normal and osteoarthritic human articular chondrocytes. Identification as the type I receptor and analysis of binding kinetics and biologic function. Arthritis Rheum. 1992;35:530-540.
21. Sadouk MB, Pelletier JP, Tardif G, Kiansa K, Cloutier JM, Martel-Pelletier J. Human synovial fibroblasts coexpress IL-1 receptor type I and type II mRNA. The increased level of the IL-1 receptor in osteoarthritic cells is related to an increased level of the type I receptor. Lab Invest. 1995;73:347-355.
22. Smith GN Jr, Yu LP Jr, Brandt KD, Capello WN. Oral administration of doxycycline reduces collagenase and gelatinase activities in extracts of human osteoarthritic cartilage. J Rheumatol. 1998;25:532-535.
23. Gouze JN, Bordjji K, Gulberti S, et al. Interleukin-1beta down-regulates the expression of glucuronosyltransferase I, a key enzyme priming glycosaminoglycan biosynthesis: influence of glucosamine on interleukin-1beta-mediated effects in rat chondrocytes. Arthritis Rheum. 2001;44:351-360.
24. Vincenti MP, Brinckerhoff CE. Early response genes induced in chondrocytes stimulated with inflammatory cytokine interleukin-1beta. Arthritis Res. 2001;3:381-388.
25. Martin MU, Wesche H. Summary and comparison of the signaling mechanisms of the Toll/interleukin-1 receptor family. Biochim Biophys Acta. 2002;1592:265-280.
26. Fan Z, Bau B, Yang H, Soeder S, Aigner T. freshly isolated osteoarthritic chondrocytes are catabolically more active than normal chondrocytes, but less responsive to catabolic stimulation with interleukin-1beta. Arthritis Rheum. 2005;52:136-143.
27. Kobayashi M, Squires GR, Mousa A, et al. Role of interleukin-1 and tumor necrosis factor alpha in matrix degradation of human osteoarthritic cartilage. Arthritis Rheum. 2005;52:128-135.
28. Verma P, Dalal K. ADAMTS-4 and ADAMTS-5: key enzymes in osteoarthritis. J Cell Biochem. 2011;112:3507-3514.
29. Meszaros E, Malemud CJ. Prospects for treating osteoarthritis: enzyme-protein interactions regulating matrix metalloproteinase activity. Ther Adv Chronic Dis. 2012;3:219-229.
30. Pelletier JP, Mineau F, Ranger P, Tardif G, Martel-Pelletier J. The increased synthesis of inducible nitric oxide inhibits IL-1Ra synthesis by human articular chondrocytes: possible role in osteoarthritic cartilage degradation. Osteoarthritis Cartilage. 1996;4:77-84.
31. Héraud F, Héraud A, Harmand MF. Apoptosis in normal and osteoarthritic human articular cartilage. Ann Rheum Dis. 2000;59:959-965.
32. Mathy-Hartert M, Hogge L, Sanchez C, Debby-Dupont G, Crieland JM, Henrotin Y. Interleukin-1beta and interleukin-6 disturb the antioxidant enzyme system in bovine chondrocytes: a possible explanation for oxidative stress generation. Osteoarthritis Cartilage. 2008;16:756-763.
33. Calich AL, Domiciano DS, Fuller R. Osteoarthritis: can anti-cytokine therapy play a role in treatment? Clin Rheumatol. 2010;29:451-455.
34. Fernandes JC, Martel-Pelletier J, Pelletier JP. The role of cytokines in osteoarthritis pathophysiology. Biotherapy. 2002;39:237-246.
35. Kaplan M, Martel-Pelletier J, Lajeunesse D, Pelletier JP, Fahmi H. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol. 2011;7:33-42.
36. Lahm A, Kasch R, Mrosek E, et al. Semiquantitative analysis of ECM affinity for IL-1beta. Proc Natl Acad Sci U S A. 2001;98:1194-1198.
37. Scanzello CR, Goldring SR. The role of synovitis in osteoarthritis pathogenesis. Bone. 2012;51:249-257.
38. Xue F, Zhang C, He Z, Ding L, Xiao H. Analysis of critical molecules and signaling pathways in osteoarthritis and rheumatoid arthritis. Mol Med Rep. 2013;7:603-607.
39. Rutgers M, Saris DB, Dhert WJ, Creemers LB. Cytokine profile of autologous conditioned serum for treatment of osteoarthritis, in vitro
effects on cartilage metabolism and intra-articular levels after injection. Arthritis Res Ther. 2010;12:R114.

40. Frizziero A, Giannotti E, Oliva F, Masiero S, Maffulli N. Autologous conditioned serum for the treatment of osteoarthritis and other possible applications in musculoskeletal disorders. Br Med Bull. 2013;105:169-184.

41. Frisbie DD, Ghivizzani SC, Robbins PD, Evans CH, Maffulli N. Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Ther. 2002;9:12-20.

42. Huggins SS, Suchodolski JS, Bearden RN, Steiner JM, Saunders WB. Serum concentrations of canine interleukin-1 receptor antagonist protein in healthy dogs after incubation using an autologous serum processing system. Res Vet Sci. 2015;101:28-33.

43. Frisbie DD. Autologous-conditioned serum: evidence for use in the knee. J Knee Surg. 2015;28:63-66.

44. Mobasher A. The future of osteoarthritis therapeutics: targeted pharmacological therapy. Curr Rheumatol Rep. 2013;15:385.

45. Evans CH, Huard J. Gene therapy approaches to regenerating the musculoskeletal system. Nat Rev Rheumatol. 2015;11:234-242.

46. Rai MF, Sandell LJ. Emerging concepts in gene therapy for osteoarthritis. J Am Acad Orthop Surg. 2015;23:e56-e57.

47. Tao K, Rey-Rico A, Frisch J, et al. rAAV-mediated combined gene transfer and overexpression of TGF-beta and SOX9 remodels human osteoarthritic articular cartilage. J Orthop Res. 2016;34:2181-2190.

48. Geurts J, Arntz OJ, Bennink MB, Joosten LA, van den Berg WB, van de Laar MA. Treatment of experimental equine osteoarthritis by in vivo delivery of a nonviral vector containing an SOX9 regulatory promoter is a safer mode of gene therapy for arthritis. Gene Ther. 2007;14:1632-1638.

49. Gabner S, Hlavaty J, Velde K, Renner M, Jenner F, Egerbacher M. Inflammation-induced transgene expression in genetically engineered equine mesenchymal stem cells. J Gene Med. 2016;18:154-164.

50. Mohamed H, Chernavsky Y, Gould D. Assembly PCR synthesis of optimally designed, compact, multiplex real-time quantitative PCR and the 2-ΔΔCT method. Methods. 2001;25:402-408.

51. Egerbacher M, Wolfsberger B, Walter I, Seiberl G. Integrins mediate the effects of quinolones and magnesium deficiency on cultured rat chondrocytes. Eur J Cell Biol. 1999;78:391-397.

52. Caldwell KL, Wang J. Cell-based articular cartilage repair: the link between development and regeneration. Osteoarthrit Cartilage. 2013;21:351-362.

53. Frisbie DD, Ghivizzani SC, Robbins PD, Evans CH, McIlwraith CW. Autologous derived mesenchymal stem cells for cartilage repair. Front Genet. 2016;7:213.

54. Spees JL, Lee RH, Gregory CA. Mechanisms of mesenchymal stem/ stromal cell function. Stem Cell Res Ther. 2016;7:125.

55. Goldberg A, Mitchell K, Soans J, Kim L, Zaidi R. The use of mesenchymal stem cells for cartilage repair and regeneration: a systematic review. J Ortho Surg Res. 2017;12:39.

56. Yubo M, Yanyan L, Li L, Tao S, Bo L, Lin C. Clinical efficacy and safety of mesenchymal stem cell transplantation for osteoarthritis treatment: a meta-analysis. PLoS ONE. 2017;12. https://doi.org/10.1371/journal.pone.0175449.

57. Leyh M, Seitz A, Dürselen L, et al. Osteoarthritic cartilage explants affect extracellular matrix production and composition in cocultured bone marrow-derived mesenchymal stem cells and articular chondrocytes. Stem Cell Res Ther. 2014;5:77.

58. Sozzi RA, Welter JF, Correa D, Caplan AL. Chondrogenic differentiation of mesenchymal stem cells: challenges and unfulfilled expectations. Tiss Eng Part B Rev. 2014;20:596-608.

59. Cui GH, Wang YY, Li CJ, Shi CH, Wang WS. Efficacy of mesenchymal stem cells in treating patients with osteoarthritis of the knee: a meta-analysis. Exp Ther Med. 2016;12:3390-3400.

60. Lang A, Neuhaus J, Pfeifferenberger M, et al. Optimization of a nonviral transfection system to evaluate Cox-2 controlled interleukin-4 expression for osteoarthritis gene therapy in vitro. J Gene Med. 2014;16:352-363.

61. Kohn DB. Historical perspective on the current renaissance for hematopoietic stem cell gene therapy. Hematol Oncol Clin North Am. 2013;27:711-735.

62. White M, Whittaker R, Gándara C, Stoll EA. A guide to approaching regulatory considerations for lentiviral-mediated gene therapies. Hum Gene Ther Methods. 2017;28:163-176.

63. Bresnihan B, Alvaro-Gracia JM, Cobb M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 1998;41:2196-2204.

64. Iqbal I, Fleischmann R. Treatment of osteoarthritis with anakinra. Curr Rheumatol Rep. 2007;9:31-35.
80. Fox BA, Stephens MM. Treatment of knee osteoarthritis with orthokine-derived autologous conditioned serum. Expert Rev Clin Immunol. 2010;6:335-345.

81. Chen B, Qin J, Wang H, Magdalou J, Chen L. Effects of adenovirus-mediated bFGF, IL-1Ra and IGF-1 gene transfer on human osteoarthritic chondrocytes and osteoarthritis in rabbits. Exp Mol Med. 2010;42:684-695.

82. Goodrich LR, Phillips JN, McIlwraith CW, et al. Optimization of scAAV1-Ra in vitro and in vivo to deliver high levels of therapeutic protein for treatment of osteoarthritis. Mol Ther Nucleic Acids. 2013;2:e70.

83. Watson RS, Broome TA, Levings PP, et al. scAAV-mediated gene transfer of interleukin-1 receptor antagonist to synovium and articular cartilage in large mammalian joints. Gene Ther. 2013;20:684-695.

84. Khoury M, Adriaansen J, Vervoordeldonk MJ, et al. Inflammation-inducible anti-TNF gene expression mediated by intra-articular injection of serotype 5 adenov-associated virus reduces arthritis. J Gene Med. 2007;9:596-604.

85. Meijer H, Reinecke J, Becker C, Tholen G, Wehling P. The production of anti-inflammatory cytokines in whole blood by physico-chemical induction. Inflamm Res. 2003;52:404-407.

86. Leclerc GM, Boockfor FR, Faught WJ, Frawley LS. Development of a destabilized firefly luciferase enzyme for measurement of gene expression. Biotechniques. 2000;29:590-591, 594-595, 598

87. Rai MF, Rachakonda PS, Manning K, et al. Quantification of cytokines and inflammatory mediators in a three-dimensional model of inflammatory arthritis. Cytokine. 2008;42:8-17.

88. Abouheif MM, Nakasa T, Shibuya H, Niimoto T, Kongcharoensombat W, Ochi M. Silencing microRNA-34a inhibits chondrocyte apoptosis in a rat osteoarthritis model in vitro. Rheumatology. 2010;49:2054-2060.

89. Johnson CI, Argyle DJ, Clemens DY. In vitro models for the study of osteoarthritis. Vet J. 2016;209:40-49.

90. Caron MM, Emans PJ, Coolsen MM, et al. Redifferentiation of dedifferentiated human articular chondrocytes: comparison of 2D and 3D cultures. Osteoarthritis Cartilage. 2012;20:1170-1178.

91. Minegishi Y, Hosokawa K, Tsumaki N. Time-lapse observation of the dedifferentiation process in mouse chondrocytes using chondrocyte-specific reporters. Osteoarthritis Cartilage. 2013;21:1968-1975.

92. Abe H, Sakai T, Ando W, et al. Synovial joint fluid cytokine levels in hip disease. Rheumatology. 2014;53:165-172.

93. Tsuchida AI, Beekhuizen M, Hart MC, et al. Cytokine profiles in the joint depend on pathology, but are different between synovial fluid, cartilage tissue and cultured chondrocytes. Arthritis Res Ther. 2014;16:441.

94. van Buul GE, Villafuertes E, Bos PK, et al. Mesenchymal stem cells secrete factors that inhibit inflammatory processes in short-term osteoarthritic synovium and cartilage explant culture. Osteoarthritis Cartilage. 2012;20:1186-1196.

95. Tang J, Cui W, Song F, et al. Effects of mesenchymal stem cells on interleukin-1β-treated chondrocytes and cartilage in a rat osteoarthritic model. Mol Med Report. 2015;12:1753-1760.

SUPPORTING INFORMATION
Additional Supporting Information may be found online in the supporting information tab for this article.

How to cite this article: Gabner S, Ertl R, Velde K, et al. Cytokine-induced interleukin-1 receptor antagonist protein expression in genetically engineered equine mesenchymal stem cells for osteoarthritis treatment. J Gene Med. 2018;20:e3021. https://doi.org/10.1002/jgm.3021